The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

Studies designed, executed, and funded by an Alkermes company.

Filter Publications
Therapeutic Area:
Publication Type:
Showing 10 of 108 results
Sort by date: Descending
Nov 2026
A big picture perspective on narcolepsy and cardiovascular health: a plain language summary of publication
Future Cardiology
AUTHOR(S)

Grandner MA, Morse AM, Avidan AY, Kushida CA, Krahn LE, Weaver C, Gudeman J

Nov 2026
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients with Bipolar I Disorder
Advances in Therapy
AUTHOR(S)

Jain R, Panchmatia HR, Hughes AG, Doane MJ, Oyedeji HE, Cutler AJ

Nov 2026
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients with Schizophrenia
Advances in Therapy
AUTHOR(S)

Cutler AJ, Panchmatia HR, Hughes AG, Doane MJ, Oyedeji HE, Jain R

Aug 2026
Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Neurology
AUTHOR(S)

Plazzi G, Grunstein RR, Mignot E, Lammers GJ, Plante DT, Buntinx E, Del Río Villegas R, Chen H, Lovett A, Doane MJ, Hopkinson C, Rege B, Himes J, Dauvilliers Y

Aug 2026
Targeting Orexin 2 Receptors in Idiopathic Hypersomnia and Narcolepsy: A Randomised Phase 1b Proof-Of-Concept Study of Alixorexton
Journal of Sleep Research
AUTHOR(S)

Grunstein RR, Yee BJ, Chapman JL, Tai JE, Sivam S, Hopkinson C, Smith DG, Lovett A, Liu S, Yagoda S, Rege B

Mar 2026
The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With Schizophrenia
The Journal of Clinical Psychiatry
AUTHOR(S)

McIntyre RS, Matthews DM, Arevalo C, McDonnell D, Correll CU

Aug 2025
Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia
Neuropsychiatric Disease and Treatment
AUTHOR(S)

Weiden PJ, Strand LN, Doane MJ, Arevalo C, McGrory JA, Achtyes ED, Harvey PD, Kane JM, Saklad SR, Trotter J, Velligan DI

Jul 2025
Healthcare Resource Utilization 6 Months Before and After Olanzapine/Samidorphan Initiation: Real-World Assessment of Patients with Schizophrenia or Bipolar I Disorder
Advances in Therapy
AUTHOR(S)
Cutler AJ, Panchmatia HR, Hughes AG, Webb NS, Doane MJ, Jain R
May 2025
Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen in Patients with Schizophrenia
Advances in Therapy
AUTHOR(S)
Lauriello J, Doane MJ, McGrory JA, Hughes AG, Strand LN
Apr 2025
Treatment patterns and healthcare resource use among veterans initiating medication for incident moderate-to-severe alcohol use disorder
The American Journal on Addictions
AUTHOR(S)

Grebla R, Kauf TL, Lax A, Cook EE, Lin Y, Liu J, Liu S, O'Sullivan AK, Shi L, Shi S, Sullivan MA, Swallow E, Witkiewitz K, Drexler K